Press releases
- Carisma Therapeutics Announces Changes to its Board of Directors
- Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna
- Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors
- Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum
- Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders
- Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference
- Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
- Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024
- Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference
More ▼
Key statistics
On Thursday, Carisma Therapeutics Inc (W2J:FRA) closed at 1.23, 32.51% above the 52 week low of 0.926 set on Jun 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.27 |
---|---|
High | 1.27 |
Low | 1.23 |
Bid | 1.26 |
Offer | 1.31 |
Previous close | 1.27 |
Average volume | 3.10k |
---|---|
Shares outstanding | 41.54m |
Free float | 28.18m |
P/E (TTM) | -- |
Market cap | 57.74m USD |
EPS (TTM) | -2.01 USD |
Data delayed at least 15 minutes, as of Jul 04 2024 14:29 BST.
More ▼